编辑专栏文章 - 后台系统

编辑专栏文章

编辑专栏文章

文章标题：

标　　签：

关键字：

文章分类：

文章主图*

点击“Select image”更换图片

Select image Change Remove

注意! 最佳图片尺寸800*800

内容详情：

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><a href="http://www.india-drugstore.com/p/zhuanti_detail.php?id=1915"><span style="color:#3498db;"><strong><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">莫博替尼</font></span></span></span></span></span></span></strong></span></a><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><a href="http://www.india-drugstore.com/p/zhuanti_detail.php?id=1915"><span style="color:#3498db;"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑"><strong>Mobocertinib</strong></font></span></span></span></span></a><span style="color:#666666"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">是专门设计用于选择性靶向EGFR ex20ins突变的口服酪氨酸激酶抑制剂（TKI）。早期研究显示，Mobocertinib单药治疗的客观缓解率（ORR）高达43%，无进展生存期（PFS）超过半年以上</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#666666"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">，</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#666666"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">研究数据令人欣慰</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#666666"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">，用来评价</font><font face="微软雅黑">EGFR/HER2抑制剂莫博替尼治疗EGFR / HER2突变的安全性，药代动力学和抗肿瘤活性。</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#666666"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">根据2021年ASCO会议上公布的数据，96例局部晚期/转移性EGFR ex20ins NSCLC患者，所有患者每天一次口服TAK788（160mg）。</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#666666"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">根据国际</font></span></span></span></span></span></span></span><a href="https://www.cancer123.com/types/lung-cancer/"><span class="15" style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#23aa1c"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">肺癌</font></span></span></span></span></span></span></span></a><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#666666"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">研究协会</font><font face="微软雅黑">(IASLC) 2021年世界</font></span></span></span></span></span></span></span><a href="https://www.cancer123.com/types/lung-cancer/"><span class="15" style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#23aa1c"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">肺癌</font></span></span></span></span></span></span></span></a><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#666666"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">大会期间公布的</font><font face="微软雅黑">1/2期试验数据，Mobocertinib(原TAK-788)治疗EGFR外显子20插入阳性转移性非小细胞</font></span></span></span></span></span></span></span><a href="https://www.cancer123.com/types/lung-cancer/"><span class="15" style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#23aa1c"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">肺癌</font></span></span></span></span></span></span></span></a><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#666666"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">(NSCLC)患者具有有意义的临床益处和可接受的耐受性，这些患者既往接受</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#666666"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">EGFR TKIs（酪氨酸激酶抑制剂 ）治疗后，疾病控制时间至少6个月。</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><font color="#666666" face="微软雅黑"><span style="font-size: 16px;">详情可以咨询印度大药房工作人员。</span></font></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><font color="#666666" face="微软雅黑"><span style="font-size: 16px;"><img alt="" src="../upload/64a3e593074c7195432148.jpg" style="width: 525px; height: 700px;" /></span></font></p>

首页显示：

显示不显示

热门文章：

是否

阅读：